ClinicalTrials.gg
Active, not recruitingNCT06048185SUSTAINUpdated Mar 24, 2025

Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study

An observational study in Stargardt Disease, sponsored by Nanoscope Therapeutics Inc.. Active, not recruiting at 2 sites in United States. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by Nanoscope Therapeutics Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
6
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Stargardt Disease with a site in United States — 16 open to participants now, 25 under way, 3 of them phase 3. Stargardt Disease · United States.

Planned enrollment
15th of 16
6 · median 63
Started
2023
with 1 other
Observational
16 of 42
8 open now
Primary completion
2027-05
later than 5 of 24 live
Registered
26th of 42
by date
Lead sponsor
3 of 42
Nanoscope Therapeutics Inc.

Among the 42 studies in Stargardt Disease with a site in United States, this one is the 15th largest by planned enrollment of the 16 observational ones that give a count, is one of 2 that started in 2023, is one of 16 observational ones, reaches primary completion later than 5 of the 24 other live ones, and was the 26th registered.

Stargardt Disease

68 studies on the registry are indexed under Stargardt Disease; 27 are open to participants now.

Browse Stargardt Disease studies →

Open to participants now

16 of the 42 studies in Stargardt Disease with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Stargardt Disease studies recruiting now, 15 (63%) set no upper age limit and 7 (29%) stop at 75 or younger; 13 take children under 18; 6 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Stargardt Disease with a site in United States, or all of them as a file.
02

Study summary

The current study is a non-interventional long-term safety follow-up of the subjects who completed STARLIGHT, in accordance with FDA guidance on recipients of human gene therapy products.

Read the detailed description

This study is designed to follow subjects with Stargardt Disease (SD) previously enrolled in study NTXMCO-004 (STARLIGHT, NCT05417126). In that study, all 6 enrolled subjects received MCO-010, an ambient light-activated, Multi-Characteristic Opsin (MCO) transgene in an adeno-associated virus serotype 2 (AAV2) vector via intravitreal injection (IVT). MCO-010 has the potential to restore vision irrespective of the underlying gene mutation, and because it is directed at bipolar retinal cells, intact photoreceptors are not required. Further details on MCO-010 and the underlying disease under investigation are included in the protocol for STARLIGHT and are not repeated herein

03

Conditions studied

  • Stargardt Disease

Keywords

  • Eye Diseases
  • Retinal Degeneration
  • Retinal Dystrophy
  • Eye Diseases, Hereditary
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population eligible to participate will comprise of the 6 subjects previously enrolled in STARLIGHT.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects are eligible to be included in the study only if all of the following criteria apply:

    1. Previously enrolled in study NTXMCO-004 study
    2. Able to comprehend and give .
    3. Able to comply with testing and all protocol tests.
    4. Agree to participate for the full 4-year study duration to the best of their ability and barring any unforeseen circumstances.

Exclusion criteria

Exclusion Criteria:

  • Not applicable. Subjects will be included in this study and will be consented after completion of all assessments at the Week 48 visit for the STARLIGHT study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
6 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • BiologicalGene Therapy Product-MCO-010

    The MCO-010 is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette

06

What researchers measure

Primary outcomes

  1. Assessment of the long-term safety profile of a single intravitreal injection of MCO-010

    Assessment of incidences, nature, and severity of treatment emergent adverse events (TEAEs), serious adverse events (SAEs); intraocular inflammation graded through ocular exam; clinical examination, and intraocular pressure.

    Time frame: 204 weeks

Secondary outcomes

  1. Evaluation of the long-term effects on visual acuity of a single intravitreal injection of MCO-010; 1.2E11 gc/eye

    Change from baseline in BCVA over time in the study eye and fellow eye

    Time frame: 204 weeks

  2. Exploration of the long-term impact of MCO-010 on retinal anatomy

    Assessment of fundus photography and optical coherence tomography (OCT) outcomes over time

    Time frame: 204 weeks

  3. Assessment of the long-term durability of MCO-010 induced on gene reporter expression

    Change from baseline of fundus fluorescence intensity of reporter (mCherry) over time in the study eye and fellow eye

    Time frame: 204 weeks

07

Study locations

2 sites
  • Nanocope Clnical Site
    Miami, Florida 33136, United States
  • Nanoscope Clinical Site
    McAllen, Texas 78503, United States
08

References and documents

Individual participant data

Plan to share: Yes — The results of the clinical trial will be made available when the study is completed. The results will be published on this site and be available to conference presentations and publications.

Time frame: Within a year from the long term monitoring data availability

Access criteria: IPD sharing access will be subject to data transfer agreement. IPD generated as part of this clinical study may be subject to patient confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for May 2027, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Sep 21, 2023
StartActual
Oct 19, 2023
Primary completionEst.
May 2027
CompletionEst.
Jul 2027
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06048185
Lead sponsor
Nanoscope Therapeutics Inc.
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Oct 19, 2023
Primary completion
May 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Mar 24, 2025

Study contacts

Dr. Samarendra Mohanty
study director · Nanoscope Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion